A picture to read: NICE gout management guidelines recommended summary of the guidelines consensus

Edited and sorted out by Yimaitong, please do not reprint
without authorization.

Gout is a long-term condition that can cause significant pain and debilitation
.
NSAIDs are commonly used in gout attacks, and for recurrent gouts, they need to be combined with lifestyle modifications or other uric acid-lowering drugs
.
However, only one-third of patients with gout receive reasonable uric acid-lowering therapy (ULT), and only one-third of these patients have blood uric acid levels effectively controlled
.
In short, there are still many unmet needs for the management of
gout.
Previously, in June, the UK's National Institute for Health and Clinical Excellence (NICE) had published guidelines for the diagnosis and management of gout, providing guidance on diagnosis, outbreak management and long-term management
.

Recommended Reading: 2022 New Gout Guidelines, Diet, Acute and Long-term Management | Guide consensus

On August 30, the journal BMJ (Impact Factor 93.
333) published a summary of the NICE gout guidelines, which more intuitively presented the guidelines management recommendations
.
See the figure
below for details.

Gout is a long-course disease that, if not treated in a timely and effective manner, usually leads to frequent attacks and even progression to tophi and chronic gout
.
In current uric acid-lowering therapy, standard therapy (< 360 μmol/L [6 mg/dl]) is critical to improve quality of life, pain, joint swelling and tenderness, and to reduce adverse events
.
Allopurinol or febuxostat can be used as first-line uric acid-lowering therapy
in patients without major cardiovascular disease.
In addition, follow-up monitoring should be used as a long-term management measure
for gout.

Download link:

References: Neilson J, Bonnon A, Dickson A, Roddy E; Guideline Committee.
Gout: diagnosis and management-summary of NICE guidance.
BMJ.
2022 Aug 30; 378:o1754.
doi: 10.
1136/bmj.
o1754.
PMID: 36041743.